Patent intelligence · US
US 2025034260
FCRN ANTAGONISTS FOR TREATMENT OF IGG-RELATED DISEASES AND DISORDERS
FCRN ANTAGONISTS FOR TREATMENT OF IGG-RELATED DISEASES AND DISORDERS
Patent details — US 2025034260
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 30, 2025
- Expiration
- Jan 25, 2045
- Applicant
- ABLYNX NV [BE]
- CPC classes
- A61K 39/ 00 A I, A61P 37/ 06 A I, A61P/3706
Quick answer
US 2025034260 (FCRN ANTAGONISTS FOR TREATMENT OF IGG-RELATED DISEASES AND DISORDERS) is held by ABLYNX NV [BE]. Status: granted. Granted Jan 30, 2025. Expires Jan 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABLYNX NV [BE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 00 A I, A61P 37/ 06 A I, A61P/3706
More from ABLYNX NV [BE]
Related pharmaceutical patents in our USPTO index.
-
WO 2026078159
AGENTS D'ACTIVATION DE CELLULES IMMUNITAIRES ET PROCÉDÉS LES COMPRENANT
granted -
WO 2026030375
NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
granted -
WO 2025262150
MOLÉCULES DE RECRUTEMENT D'ANTICORPS
granted -
AR 133055
DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1
granted -
MX 2025007399
PROTEIN-BASED CONJUGATION CARRIERS
granted -
WO 2025133166
VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE
granted -
WO 2025133252
DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5
granted -
WO 2025133253
EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE
granted
Frequently asked questions
What is US patent 2025034260?
US 2025034260 (FCRN ANTAGONISTS FOR TREATMENT OF IGG-RELATED DISEASES AND DISORDERS) is held by ABLYNX NV [BE]. Status: granted. Granted Jan 30, 2025. Expires Jan 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2025034260?
ABLYNX NV [BE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2025034260 expire?
Our index shows an expiration date of Jan 25, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.